Document is current
Any future updates will be listed below
-
Authors
Inker, Lesley A. http://orcid.org/0000-0003-2820-9482
Collier, Willem
Greene, Tom
Miao, Shiyuan
Chaudhari, Juhi
Appel, Gerald B.
Badve, Sunil V.
Caravaca-Fontán, Fernando http://orcid.org/0000-0002-5830-9663
Del Vecchio, Lucia
Floege, Jürgen
Goicoechea, Marian
Haaland, Benjamin
Herrington, William G.
Imai, Enyu
Jafar, Tazeen H. http://orcid.org/0000-0001-7454-8376
Lewis, Julia B.
Li, Philip K. T. http://orcid.org/0000-0001-9879-8388
Maes, Bart D. http://orcid.org/0000-0001-5084-5130
Neuen, Brendon L.
Perrone, Ronald D.
Remuzzi, Giuseppe http://orcid.org/0000-0002-6194-3446
Schena, Francesco P.
Wanner, Christoph
Wetzels, Jack F. M. http://orcid.org/0000-0002-0650-6921
Woodward, Mark
Heerspink, Hiddo J. L.
,
Estacio, Raymond O.
Hanratty, Rebecca
Chalmers, John
Canetta, Pietro
Barrett, Brendan
Neal, Bruce
Perkovic, Vlado
Mahaffey, Kenneth W.
Johnson, David
Jardine, Meg
von Eynatten, Maximilian
Verde, Eduardo
Verdalles, Ursula
Arroyo, David
Chapman, Arlene
Torres, Vicente
Yu, Alan
Brosnahan, Godela
Hannedouche, Thierry
Chow, Kai-Ming
Szeto, Cheuk-Chun
Leung, Chi-Bon
Xie, Di
Hou, Fan Fan
Dwyer, Jamie
Pohl, Marc A.
Raz, Itamar
Hunsicker, Lawrence G.
Vanacker, An
Malfait, Thomas
Maschio, Giuseppe
Locatelli, Francesco
Blankestijn, Peter J.
van Zuilen, Arjan
Kobayashi, Fumiaki
Makino, Hirofumi
Chan, Juliana C. N.
Andrulli, Simeone
Pozzi, Claudio
Casartelli, Donatella
Praga, Manuel
Trujillo, Hernando
Cavero, Teresa
Sevillano, Angel
Ruggenenti, Piero
Perna, Annalisa
Carrara, Fabiola
Keane, William F.
Manno, Carlo
Haynes, Richard
Herrington, William G.
Baigent, Colin
Landray, Martin
Rauen, Thomas
Seikrit, Claudia
Wied, Stefanie
Toto, Robert D.
de Jong, Paul E.
Saddelli, Mauro
- License Information
-
More Information
Article History
Received: 31 October 2022
Accepted: 24 May 2023
First Online: 17 June 2023
Competing interests
: L.A.I. reports funding from National Institutes of Health (NIH), National Kidney Foundation (NKF), Omeros, Chinnocks, and Reata Pharmaceuticals for research and contracts to Tufts Medical Center; consulting agreements to Tufts Medical Center with Tricida; and consulting agreements with Diamerix. W.H.C. reports funding from the NKF to his institute for his graduate research assistantship. T.G. reports grant support from the NKF, Janssen Pharmaceuticals, Durect Corporation and Pfizer and statistical consulting from AstraZeneca, CSL and Boehringer Ingleheim. B.H. consults for the NKF, Proxima Clinical Research, Value Analytics Health and Guidepoint Global. G.B.A. reports funding for research studies through Columbia University, Calliditas, Travere, Novartis, Equillium, Roche, Sanofi, Reata, Apellis, Nephronet, Goldfinch and Vertex; consultations for Sanofi-Genzyme, Roche/Genetech, Apellis, Novartis, Travere, Calliditas, Glaxo and Aurinia; and speaker’s honoraria from GlaxoSmithKline and Aurinia, both on lupus nephritis. S.V.B. reports funding from the National Health and Medical Research Council of Australia; has served on the advisory boards of Bayer, AstraZeneca and Vifor Pharma; and has received speaker’s honoraria from Bayer, AstraZeneca, Pfizer and Vifor Pharma, all fees paid to the George Institute for Global Health. L.D.V. was an advisory board member for Travere. L.D.V. is also National Leader for the PROTECT Study and the VISIONARY study. J.F. reports lecture and consulting honoraria from Alynlam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Calliditas, Fresenius, Novartis, Omeros, Travere and Vifor and is a member of the data safety monitoring board in trials for Novo Nordisk and Visterra. W.G.H. reports personal funding from the UK Medical Research Council (MC_UU_00017/3) and Kidney Research UK (MR/R007764/1) and grants to the University of Oxford from Boehringer Ingelheim and Eli Lilly. E.I. received research funding and honoraria for lectures from AstraZeneca, Tanabe Mitsubishi, Boehringer Ingelheim, Daiich Sankyo, Kyowa Kirin and Novo Nordisk. J.B.L. is a consultant for CSL and BioVie. P.K.T.L. received speaker’s honoraria from FibroGen, AstraZeneca and Baxter. B.D.M. is the National Leader of the ASCEND-D and ASCEND-ND trials of GlaxoSmithKline and the PROTECT and DUPLEX trials of Travere and is a steering committee member for the Novartis APPLAUSE trial and the Vera Therapeutics ATACICEPT trial. B.L.N. has received fees for advisory boards, scientific presentations, continuing education, steering committee roles and travel from AstraZeneca, Bayer, Boehringer Ingelheim, Cambridge Healthcare, Janssen and Medscape, with all honoraria paid to his institution. R.D.P. received research support from Otsuka, Reata, Kadmon, Sanofi Genzyme and the US Department of Defense (TAME PKD); has been a member of steering committees for Sanofi Genzyme, Otsuka and TAME PKD, with fees paid to employing institutions; and has provided consultancy for Navitor, Palladiobio, Reata and Otsuka. G.R. has had consultancy agreements with Alexion Pharmaceuticals, Janssen, Akebia Therapeutics, Biocryst Pharmaceuticals, Menarini Ricerche SpA and AstraZeneca and speaker honoraria/travel reimbursement from Boehringer Ingelheim and Novartis. M.W. reports consulting fees from Amgen and Freeline, paid to him. H.J.L.H. received grant support from the NKF to his institute and is a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli Lilly, Gilead, GoldFinch, Janssen, Merck, Novo Nordisk and Travere Pharmaceuticals. S.M., J.C., M.G., F.C.F., T.H.J., F.P.S., C.W. and J.F.M.W. have no conflicts to report associated with this manuscript.
